mcJeremy N Rich Laboratory

Rich Lab Publications

  1. Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich JN, Bigner DD, Schold SC Jr. (1992).  Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.  J Natl Cancer Inst 84: 1926-1931.
  2. Rich JN, Elion GB, Wellner D, Colvin OM, Groothuis DR, Hilton JH, Sclageter KE, Bigner DD, Griffith OW, Friedman HS (1995).  The effect of l-amino acid oxidase on activity of melphalan against an intracranial xenograft.  Cancer Chemother Pharmacol 36: 379-384.
  3. Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold SC Jr (1998). Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16(11): 3570-3575.
  4. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998). DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16(12): 3851-3857.
  5. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughesy T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999).  Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17(5):1516-1525.
  6. Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines (1999). J Biol Chem 274(49): 35053-35058.
  7. Friedman HS, Pluda J, Quinn JA, Ewesuedo RB, Long L, Friedman AH, Cokgor I, Colvin OM, Haglund MM, Ashley DM, Rich JN, Sampson J, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Stewart ES, Tourt-Uhlig S, Garcia-Turner AM, Herndon JE 2nd, Bigner DD, Dolan ME (2000).  Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18(20): 3522-8.
  8. Rich JN, Borton AJ, Wang X-F (2001). Transforming growth factor-beta signaling in cancer. Microsc Res Tech 52(4): 363-373.
  9. Rich JN, Guo C, Bigner DD, McLendon R, Wang X-F, Counter CM (2001).  A genetically tractable model of human glioma formation.  Cancer Res 61(9): 3556-3560.
  10. Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS (2001).  Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.  Neuro-oncol 3(4): 246-250.
  11. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, II, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich J, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao X-G, Zalutsky MR, and Bigner DD (2002).  Phase II trial results of murine 131I-labeled anti-tenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.  J Clin Oncol 20: 1389-1397.
  12. Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, Counter CM (2002).  Distinct requirements for Ras oncogenesis in human versus mouse cells.  Genes Dev 16(16): 2045-2057.
  13. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS  (2002). Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.  J Clin Oncol 20(9): 2277-2283.
  14. Rich JN (2003). The role of transforming growth factor-beta in primary brain tumors.  Front Biosci 8: E245-E260.
  15. Quinn, JA, Reardon, DA, Friedman, AH, Rich, JN, Sampson, JH, Provenzale, JM, McLendon, RE, Gururangan, S, Bigner, DD, Herndon II, JE, Avgeropoulos, N, Finlay, J, Tourt-Uhlig, S, Affronti, ML, Evans, B, Stafford-Fox, V, Zaknoen, S, Friedman, HS  (2003). Phase II trial of temozolomide in patients with progressive low grade glioma.  J Clin Oncol 21: 646-651.
  16. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model.  J Biol Chem 278(18):15951-15957.
  17. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE II, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, and Pastan I (2003). Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)‑α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.  J Neuro-Oncol 65: 27-35.
  18. Rich JN, Reardon DA, Peery T, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, Mclendon RE, Kao JC, Stenzel TT, Rasheed BAK, Tourt-Uhlig SE, Dowell JM, Herndon JE, II, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004).  Phase II trial of gefitinib (ZD1839) in recurrent glioblastoma. J Clin Oncol 22: 133-42.
  19. Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS (2004).  Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-onc 6: 134-144.
  20. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS (2004).  Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-onc 6: 145-154.
  21. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF (2004). Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5: 329-39.
  22. Rich JN and Bigner DD (2004). The development of novel targeted therapies in the treatment of malignant glioma. Nature Rev Drug Discov 3: 430-446.
  23. Learn CA, Hartzell TL, Archer GE, Rich JN, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2004). Inhibition of cell cycle progression, downstream signaling and invasion of cells expressing wild-type epidermal growth factor receptor (EGFR) but not mutant EGFR variant III by the EGFR tyrosine kinase inhibitor gefitinib.  Clin Cancer Res 10: 3216-3224.
  24. Bos TJ, Cohn SL, Kleinman HK, Koblinski J, Murphy-Ullrich JE, Podhajcer OL, Rempel SA, Rich JN, Rutka JT, Sage EH, Thompson EW (2004). International Hermelin Brain Tumor Symposium on Matricellular Proteins in Normal and Cancer Cell-Matrix Interactions.  Matrix Biol 23: 64-70.
  25. Hjelmeland M, Hjelmeland A, Sathornsumetee S, Herbstreith MH, Laping NJ, Bigner DD, Wang XF, and Rich JN (2004). SB-431542, a small molecule transforming growth factor-β-receptor antagonist, inhibits human glioma cell line proliferation and motility.  Mol Cancer Ther 3: 737-745.
  26. Rich JN, Friedman HS, Dancey JE (2004). Gefitinib in glioblastoma, in reply.  J Clin Oncol 22: 2755–2756 (letter).
  27. Rich JN, Rasheed BKA, Yan H (2004). In response to: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 351: 1260 (letter).
  28. Shi Q, Bao S, Maxwell JA, Reese ED, Friedman HS, Bigner DD, Wang XF, Rich JN (2004). Secreted protein acidic, rich in cysteine (SPARC) mediates cellular survival of gliomas through AKT activation.  J Biol Chem 279(50):52200-52209.
  29. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE 2nd, Dowell JM, Friedman AH, Friedman HS.  (2005) Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.  Cancer 103(2):329-338.
  30. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese E, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN.  (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4(1):101-112.
  31. Rich JN, Hans C, Jones B, McLendon R, Rasheed BKA, Bigner DD, Dressman H, Nevins J, and West M.  (2005) Gene expression profiling and graphical association in glioblastoma survival.  Cancer Res 65(10): 4051-4058.
  32. Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. (2005) Chemotherapy and novel therapeutic approaches in malignant glioma.  Front Biosci. 10:2645-2668.
  33. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE 2nd, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS.  (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.  Cancer 104(7):1478-1486.
  34. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS.  (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.  J Clin Oncol. 23(28):7178-87.
  35. Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Reardon D, Ryan AJ,  Wheeler C, Dimery I, Bigner DD, Friedman HS.  (2005) ZD6474, A Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitor, Inhibits Central Nervous System Tumor Growth. Clin Cancer Res 11(22):8145-57.
  36. Hjelmeland AB, Hjelmeland MD, Shi Q, Hart J, Bigner DD, Wang XF, Kontos C, Rich JN.  (2005) Loss of PTEN Increases TGFβ Mediated Invasion with Enhanced SMAD3 Transcriptional Activity.  Cancer Res. 65(24):11276-81.
  37. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS.  (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.  J Clin Oncol. 23(36):9359-68.
  38. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD.  (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.  J Clin Oncol. 24(1):115-22.
  39. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, II, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN.  (2006) Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma.  Clin Cancer Res 12: 860-868.
  40. Reardon DA, Rich JN, Friedman HS, Bigner DD.  (2006) Recent advances in the treatment of malignant astrocytoma.  J Clin Oncol. 24(8):1253-65.
  41. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE II, McLendon RE, Pegram CN, Provenzale JM,  Dowell JM, Rich JN, Vredenburgh JV, Desjardins A, Sampson JH, Gururangan S, Terence Z. Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. (2006) Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J Nucl Med. 47(6):912-918.
  42. Sathornsumetee S, Rich JN.  (2006) New treatment strategies for malignant gliomas.  Expert Rev Anticancer Ther 6(7): 1087-1104.
  43. Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BKA, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. (2006) AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks growth of malignant glioma.  Cancer Res 66(17):8722-30.
  44. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, and Rich JN. (2006) Stem cell-like glioblastoma cells promote tumor angiogenesis through vascular endothelial growth factor.  Cancer Res 66(16):7843-8 (selected for margin cover article and press release).
  45. Sathornsumetee S, Rich JN.  New approaches to primary brain tumor treatment.  Anticancer Drugs. 2006 Oct;17(9):1003-16.
  46. Sathornsumetee S, Rich JN. Signal Transduction Pathways as Novel Therapeutic Targets in Malignant Glioma.  Future Neurology, in press.
  47. DeKroon R, Robinette JB, Hjelmeland AB, Wiggins E, Blackwell M, Mihovilovic M, Fujii M, York J, Hart J, Kontos C, Rich J, Strittmatter WJ. (2006) APOE4-VLDL inhibits the HDL-activated phosphatidylinositol 3-kinase/Akt Pathway via the phosphoinositol phosphatase SHIP2.
    Circ Res 2006 Oct 13;99(8):829-36.
  48. Sathornsumetee S, Rich JN.  (2006) Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs of Today, in press.
  49. Shideng Bao, Qiulian Wu, Roger E. McLendon, Yueling Hao, Qing Shi, Anita B. Hjelmeland, Mark W. Dewhirst, Darell D. Bigner and Jeremy N. Rich.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760(7 December 2006).
  50. Qing Shi, Anita B Hjelmeland, Stephen T Keir, Linhua Song, Sarah Wickman, Dowdy Jackson, Osamu Ohmori, Darell D Bignar, Henry S Friedman, Jeremy N Rich, A Novel Low-Molecular-Weight Inhibitor of Focal Adhesion Kinase, TAE226, Inhibits Glioma Growth, Molecular Carcinogenesis, 46:488-496.
  51. Qing Shi, Shideng Bao, Linhua Song, Qiulian Wu, Anita B Hjelmeland, Darell D Bignar, Jeremy N Rich, Targeting SPARC Expression Decreases Glioma Cellular Survival and Invasion Associated with Reduced Activities of FAK and ILK Kinases, Oncogene, 26(28):4084-4094 .
  52. Sith Sathornsumetee, Anita B. Hjelmeland, Stephen T. Keir, Roger E. McLendon, David Batt, Timothy Ramsey, Naeem Yusuff, B.K. Ahmed Rasheed, Mark W. Kieran, Andrea Laforme, Darell D. Bigner, Henry S. Friedman, and Jeremy N. Rich, AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma. Cancer Res. 2006 66: 8722-8730.
  53. Anita B. Hjelmeland, Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, Darell D. Bigner, Henry S. Friedman, and Jeremy N. Rich, The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol. Cancer Ther. 2007 6: 2449-2457.

 

 

About Us | Site Map | Privacy Policy | Contact Us | ©2007 Qing Shi, Jeremy Rich and/or Duke University Medical Center